Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis

Magouliotis, Dimitrios; Asprodini, Eftihia; Svokos, Konstantina; Tasiopoulou, Vasiliki S.; Svokos, Alexis; Toms, Steven

doi:10.1007/s00701-018-3536-6

Cited by 11 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a recent meta analysis [ 19 ], the median OS was increased in patients treated with TTFields with recurrent GBM (weighted mean difference [WMD], 2.55; p <0.00001) and newly diagnosed GBM (WMD, 7.48; p <0.00001). In addition, patients who received the TTField modality presented increased OS, survival at after 1 and 2 years, PFS, along with PFS at 6 months.…”

Section: Progress Of Ttfields On Human Gbm Clinical Trialmentioning

confidence: 99%

The Value of Tumor Treating Fields in Glioblastoma

Zhang

et al. 2020

J Korean Neurosurg Soc

View full text Add to dashboard Cite

Glioblastoma (GBM) is one of the most common tumors of the central nervous system, which is the most lethal brain cancer. GBM treatment is based primarily on surgical resection, combined with radiotherapy and chemotherapy. Despite the positive treatment, progression free survival and overall survival were not significantly prolonged because GBM almost always recurs. We are always looking forward to some new and effective treatments. In recent years, a novel treatment method called tumor treating fields (TTFields) for cancer treatment has been proposed. TTFields devices were approved by the Food and Drug Administration (FDA) for adjuvant treatment of recurrent and newly diagnosed GBMs in 2011 and 2015, respectively. This became the first breakthrough treatment for GBM in the past 10 years after the FDA approved bevacizumab for patients with relapsed GBM in 2009. This paper summarized the research results of TTFields in recent years and elaborated the mechanism of action of TTFields on GBM, including cell and animal experimental research, clinical application and social benefits.

show abstract

Section: Progress Of Ttfields On Human Gbm Clinical Trialmentioning

confidence: 99%

The Value of Tumor Treating Fields in Glioblastoma

Zhang

et al. 2020

J Korean Neurosurg Soc

View full text Add to dashboard Cite

show abstract

“…Glioblastoma treatment should be undertaken in a multimodal fashion, with neurosurgical intervention, radiation oncology input, and chemotherapy administration. Since TTFields represent an additional anti-cancer treatment modality with few toxicities, neuro-oncologists should consider incorporating this therapy into current treatment regimens for both newly diagnosed and recurrent glioblastoma 18,19 .…”

Section: Ttfields Device and Treatment Optionsmentioning

confidence: 99%

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Riley

San²,

Lok³

et al. 2019

JoVE

View full text Add to dashboard Cite

Glioblastoma is the most common and lethal form of brain cancer, with a median survival of 15 months after diagnosis and a 5 year survival rate of only 5% with current standard of care. Tumors often recur within 9 months following initial surgery, radiation and chemotherapy, at which point treatment options become limited. This highlights the pressing need for the development of better therapeutics to prolong survival and increase the quality of life for these patients. Tumor Treating Fields (TTFields) therapy was developed to take advantage of the effect of low frequency alternating electrical fields on cells for cancer therapy. TTFields have been demonstrated to disrupt cells during mitosis and slow tumor growth. There is also growing evidence that they act through stimulating immune responses within exposed tumors. The advantages of TTFields therapy include its noninvasive approach and increased quality of life compared to other treatment modalities such as cytotoxic chemotherapies. The Food and Drug Administration approved TTFields therapy for the treatment of recurrent glioblastoma in 2011 and for newly diagnosed glioblastoma in 2015. We report on the effects of TTFields during mitosis, the results of electric fields modeling, and proper transducer array placement. Our protocol outlines the clinical application of TTFields on a patient post-surgery, using the second-generation device.

show abstract

“…This stimulus is delivered continuously by transducers applied to a shaved scalp. In an open-label randomized trial of 695 adults with newly diagnosed glioblastoma, median survival was improved in patients assigned to wear the device during the adjuvant temozolomide phase of The Systemic Treatment of Glioma DOI: http://dx.doi.org/10.5772/intechopen.80047 standard chemoradiation compared with those assigned to standard chemoradiation alone (21 vs. 16 months) [57,58]. The requirement to carry a device and maintain a shaved scalp for the duration of treatment presents a potential burden that is not acceptable to all patients [59].…”

Section: Grade IV Gliomas: Glioblastomamentioning

confidence: 99%

The Systemic Treatment of Glioma

Camargo¹

2019

Primary Intracranial Tumors

View full text Add to dashboard Cite

Gliomas have been treated by a specialized team including neurosurgery, radiation therapy, and neuro-oncology, as well as depending on integrated sophisticated facilities and multi-professional team. Despite these huge efforts to glioma treatment, glioblastoma, one of the most frequent gliomas, has median life expectance for just 15 months, so these results are still an unmet need. Related to the systemic treatment, some cancer approaches have been revolutionized with new strategies, such as immunotherapy, although in neuro-oncology, this alternative still has challenges to overcome. Throughout this chapter, relevant information and key points will be discussed to the best way to manage systemic treatment and improve glioma overall survival.

show abstract

Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis

Abstract: TTFields are a safe and efficient novel treatment modality. More randomized controlled studies, with longer follow-up, are necessary to further assess the clinical outcomes of TTFields.

Cited by 11 publications

References 21 publications

The Value of Tumor Treating Fields in Glioblastoma

The Value of Tumor Treating Fields in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Systemic Treatment of Glioma

Contact Info

Product

Resources

About